Hopeful signs from largest remdesivir trial
The largest and most rigorous clinical trial yet of the antiviral medicine remdesivir against the coronavirus raises hopes that the drug could shorten the time to recovery. Yesterday, US National Institute of Allergy and Infectious Diseases director Anthony Fauci announced that the trial of more than 1,000 people showed that those taking remdesivir recovered in 11 days on average, compared with 15 days for those on a placebo. Results from other trials of the drug had been inconclusive. The full results of this study have yet to be published.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” Fauci said. “What it has proven is that a drug can block this virus.” A flood of small trials for various drugs has yet to convincingly show any that have boosted survival in people with COVID-19.
Nature | 5 min read
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” Fauci said. “What it has proven is that a drug can block this virus.” A flood of small trials for various drugs has yet to convincingly show any that have boosted survival in people with COVID-19.
.png)
No hay comentarios:
Publicar un comentario